跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 22,167 条关于
“Bruton tyrosine kinase inhibitor”
全部
22,167
临床试验
11,221
药物
4,307
机构
64
资讯
6,575
9年前
Ibrutinib Shows Promise in Treating Chronic Graft-Versus-Host Disease
2年前
Infection Risk With BTK Inhibitors Low, New CLL Study Finds
去年
Study Finds No Benefit in Pausing BTK Inhibitors During COVID-19 Vaccination for CLL Patients
上个月
Acanthamoeba Encephalitis in Chronic Lymphocytic Leukemia: Case Report Highlights Infection Risk with Ibrutinib
去年
Fixed-Duration Venetoclax Regimen Reduces Long-Term Costs in CLL Treatment
去年
Novel Therapies Show Promise for Chronic Spontaneous Urticaria with Complete Response Rates Exceeding 30%
去年
Zanubrutinib Shows Limited Cost-Effectiveness Against R-Bendamustine for First-Line CLL Treatment in China
去年
Study Reveals Different Effects of CLL Therapies on Blood Cell Behavior: Ibrutinib Shows Promise in Normalizing RBC Aggregation
去年
Zanubrutinib and Venetoclax Combination Shows Promise in Relapsed/Refractory CLL
去年
Liso-cel Combined With Ibrutinib Shows Promise for Relapsed/Refractory CLL and Richter Transformation
第 1 页，共 658 页
上一页
下一页
